title: The impracticality of biomedical rejuvenation therapies: translational and pharmacological barriers.
abstract: The notion that it is possible to eradicate age-related degeneration and live a life with a negligible rate of senescence solely by using a physical "repair-oriented" approach is flawed on a number of fronts. Here, I will argue that there are so many unknown variables embedded in this line of thinking that make the final result impossible to predict. Two relatively easy-to-research areas are the search for successful cross-link breakers and an effective lysosomal degradation therapy. A more complex and speculative strategy is whole-body interdiction of lengthening of telomeres (WILT). Highlighting these as examples, I argue that it is unlikely that such rejuvenation biotechnologies will be used meaningfully by the general public. The discussion assumes that although such therapies may in theory one day be developed in the laboratory, and even possibly be formulated as physical clinical therapies, these will be unusable in practical terms when applied upon humans at large. Due to inherent characteristics of our biological, evolutionary, and psychological heritage, it is implausible that curing aging will occur by using physical interventions alone.
authors: ELPIs Foundation for Indefinite Lifespans , London, United Kingdom .
authors: Marios
authors: M
authors: Kyriazis
mesh_terms: D000375:Aging; D001709:Biotechnology; D017127:Glycation End Products, Advanced / Q000627:therapeutic use; D006801:Humans; D008247:Lysosomes / Q000378:metabolism; D055118:Medication Adherence; D010600:Pharmacology; D019338:Polypharmacy; D012060:Rejuvenation / Q000502:physiology*; D016615:Telomere / Q000648:ultrastructure; D013844:Thiazoles / Q000627:therapeutic use; D057170:Translational Research, Biomedical / Q000458:organization & administration*
chemical_list: D017127:Glycation End Products, Advanced; D013844:Thiazoles; C543060:glucosepane; C406794:alagebrium